The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

Methods of preventing or treating Parkinson's disease in subjects are described where drugs are administered to subjects in effective amounts to cause the farnesylation of PARIS and the enhanced expression of PGC-1α in the brain. These methods alleviate the effects of Parkinson's disease in subjects, in part, by preventing the loss of dopamine neurons.

The present invention relates to anti-ROR1 antibodies and to methods of using anti-ROR1 antibodies. The anti-ROR1 antibodies described herein are useful for the diagnosis and treatment of diseases, such as various cancers, associated with aberrant expression of ROR1.

Described herein is fatty acid-binding protein 3 (FABP3) and/or FABP4 for diagnosing or staging peripheral artery disease (PAD) or for assessing revascularization in PAD afflicted subjects. Also described is FABP3 and/or FABP4 for distinguishing PAD patients from non-PAD patients regardless of the presence PAD symptoms, for distinguishing PAD patients with a non-compressible ABI from non-PAD patients, or for determining prognosis in PAD. Also described herein are various methods and biomarker panels for use in PAD.

A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Disclosed are a kit for testing myocardial infarction rapidly and a preparation method and use thereof. The kit comprises a strip capable of detecting three markers, namely, human myeloperoxidase (MPO), heart-fatty acid binding protein (FABP3) and cardiac troponin I(cTnI) simultaneously. The strip comprises a sample pad, a conjugate pad, a chromatographic membrane coated with three test lines and a quality control line, and a sample absorption pad. Antibodies of the three markers are all marked on the conjugate pad. The chromatographic membrane has three test lines formed by coating paired antibodies of the three markers respectively, the paired antibodies of the three markers being able to specifically combine with the three markers, respectively. The kit has advantages such as convenient operation, rapid response, high sensitivity and high specificity, point of care test, and economical and practical etc.

[Problem] To provide a mitochondria-function regulator effective for treatment or prevention of obesity, and a screening method therefore. [Solution] The mitochondria-function regulator of the present invention contains, as an active ingredient, a PGC-1β-protein function regulator synoviolin. The screening method of the present invention includes a step for causing a test substance to act on an adipose tissue cell or an individual animal, and measuring or detecting one or more of the following in the adipose tissue cell: (1) expression level of synoviolin; (2) a bond between synoviolin and PGC-1β protein; and (3) the ubiquitination of the PGC-1β protein by synoviolin.

A method for identifying an AhR-phospho-RORγt protein complex inhibitor, comprising: (a) providing a cell culture, in which cells in the culture express AhR protein and phospho-RORγt protein; (b) incubating the cell culture in the presence of a test agent; (c) assaying the level of the AhR-phospho-RORγt protein complex in the presence of the test agent; (d) comparing the level of the AhR-phospho-RORγt protein complex in the presence of the test agent with a control; and (e) identifying the test agent as the inhibitor of the AhR-phospho-RORγt protein complex when the comparing step indicates that there is a reduction in the level of the AhR-phospho-RORγt protein complex in the presence of the test agent as compared with the control. A method for identifying a GLK−IQGAP1 protein complex inhibitor is also disclosed. Use of identified inhibitors in the manufacture of a medicament for treating a disease is also disclosed.

A method of diagnosing breast cancer is disclosed. The method comprises lysing extracellular vesicles of a subject to generate a composition comprising components of extracellular vesicles; measuring the amount of MEK1 in the composition; and diagnosing the subject with breast cancer when a level of said MEK1 in said composition is above a predetermined threshold. Kits for breast cancer diagnosis are also disclosed.

There is provided a method of targeting mitochondrial biogenesis and mitochondrial transport from the cell body to axon to protect acutely demyelinated axons from degeneration. The method may comprise increasing mobilization of mitochondria from the neuronal cell body to the demyelinated axon to treat demyelinating disorders and provide a novel neuroprotective strategy for vulnerable acutely demyelinated axons. The method may comprise mitochondrial biogenesis in the demyelinated axon to treat demyelinating disorders and provide a novel neuroprotective strategy for vulnerable acutely demyelinated axons. The method comprises a variety of compounds and strategies for increasing mitochondrial transport and biogenesis to the demyelinated axon in both the peripheral and central nervous systems.